Dr. Dathan Hamann, M.D.
Dermatology (Dermatology Physician)
3400 E Mcdowell Rd
Phoenix, AZ 85008
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2014
- Medicare patients seen, 2024
- 388
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Arizona College of Medicine
- 2014Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
AZ license 54501
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Saguaro Dermatology Associates LLC (13 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 388
- Services billed
- 8,874
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Test for allergy using skin patch | 4,927 | 46 |
| Destruction of precancer skin growth, 2-14 growths | 699 | 120 |
| Established patient office or other outpatient visit, 30-39 minutes | 428 | 281 |
| Destruction of precancer skin growth, 1 growth | 182 | 145 |
| Established patient office or other outpatient visit, 20-29 minutes | 176 | 153 |
| New patient office or other outpatient visit, 45-59 minutes | 121 | 121 |
| Biopsy of related skin growth, first growth | 107 | 99 |
| Destruction of skin growth, 1-14 growths | 89 | 79 |
| Punch biopsy, first skin growth | 60 | 57 |
| New patient office or other outpatient visit, 30-44 minutes | 52 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Triamcinolone Acetonide Other prescribers in Phoenix, AZ | 118 |
| Clobetasol Propionate Other prescribers in Phoenix, AZ | 51 |
| Ketoconazole Other prescribers in Phoenix, AZ | 44 |
| Prednisone Other prescribers in Phoenix, AZ | 40 |
| Mycophenolate Mofetil Other prescribers in Phoenix, AZ | 23 |
| Fluorouracil Other prescribers in Phoenix, AZ | 23 |
| Fluocinolone Acetonide (fluocinolone/shower cap) | 20 |
| Betamethasone Dipropionate Other prescribers in Phoenix, AZ | 15 |
| Tacrolimus Other prescribers in Phoenix, AZ | 14 |
| Mupirocin Other prescribers in Phoenix, AZ | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 127 payments worth $30,300 in total to this clinician.
| Pfizer Inc. | $25,014 |
|---|---|
| Incyte Corporation | $2,724 |
| Galderma Laboratories, L.P. | $369 |
| Leo Pharma Inc. | $264 |
| Regeneron Healthcare Solutions, Inc. | $257 |
| Organon LLC | $253 |
| Janssen Biotech, Inc. | $201 |
| UCB, Inc. | $198 |
| Consulting Fee | $20,000 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $6,250 |
| Food and Beverage | $3,074 |
| Travel and Lodging | $967 |
| Education | $9.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. May 28, 2025 | Consulting Fee LITFULO · IMMUNOLOGY | $9,420 |
| Pfizer Inc. Mar 13, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $7,980 |
| Pfizer Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology | $3,125 |
| Pfizer Inc. Jun 11, 2025 | Compensation for services other than consulting (speaking, faculty) CIBINQO · Inflammation & Immunology | $3,125 |
| Incyte Corporation Dec 7, 2025 | Consulting Fee | $2,600 |
| Pfizer Inc. Feb 1, 2025 | Travel and Lodging CIBINQO · Inflammation & Immunology · travel to Rosemont, IL · in-kind | $820 |
| Pfizer Inc. Feb 1, 2025 | Travel and Lodging CIBINQO · Inflammation & Immunology · travel to Rosemont, IL · in-kind | $147 |
| AbbVie Inc. Aug 5, 2025 | Education SKYRIZI · IMMUNOLOGY · in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $164,514 in research payments for these studies, mostly to the institutions running them.
- TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
Takeda Pharmaceuticals U.S.A., Inc. - Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Sanofi US Services Inc. · Completed · NCT05991323 - A study to evaluate the safety and tolerability of maximal use Ruxolitinib Cream
Incyte Corporation - A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK)
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.